Blog

PHARMAC is seeking feedback on a proposal involving the funding of haemophilia treatments. The treatments include recombinant factor VIII (rFVIII), ...

The Minister for Health has considered the reports for all three stages of the post-market review of products used in ...

An open letter from ABPI Chief Executive, Stephen Whitehead, to the Secretary of State for Health, Jeremy Hunt MP, following ...

A new agreement for a high cost biologic drug will yield considerable savings for DHBs over the next five years, ...

The Public Release Documents from the February 2015 Drug Utilisation SubCommittee meeting are now available on the PBS website. ...

In final draft guidance published today NICE has confirmed its earlier positive draft decision recommending rivaroxaban (Xarelto, Bayer Healthcare), in ...

[:content [\2 \5 \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \space \- \space \B \r \i \t \i \s \h \space \p \a \t \i \e \n \t \s \space \s \h \o \u \l \d \space \a \d \o \p \t \space \m \o \r \e \space \\ \" \p \u \s \h \y \\ \" \space \A \m \e \r \i \c \a \n \space \a \t \t \i \t \u \d \e \s \space \w \i \t \h \space \t \h \e \i \r \space \d \o \c \t \o \r \s \space \t \o \space \g \e \t \space \d \r \u \g \s \space \t \h \e \y \space \a \r \e " ..."]]

[:content [\S \p \a \i \n \space \w \i \l \l \space \n \o \w \space \g \u \a \r \a \n \t \e \e \space \r \e \g \i \o \n \a \l \space \g \o \v \e \r \n \m \e \n \t \s \' \space \p \a \y \m \e \n \t \s \space \t \o \space \d \r \u \g \m \a \k \e \r \s \space \i \n \space \a \space \b \i \d \space \t \o \space \g \a \r \n \e \r \space \s \u \p \p \o \r \t \space \f \o \r \space \a \space \p \l \a \n \space \t \o \space \c \e \n \t \r \a \l \i \s \e " ..."]]

Commenting on the Scottish Government’s decision to establish a dedicated New Medicines Fund worth £40m, ABPI Scotland Director Andrew Powrie-Smith ...

PHARMAC is pleased to announce the approval of a proposal for azacitidine (Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid) that was ...

PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Douglas Pharmaceuticals Limited for the supply of ...

In draft guidance published today NICE has recommended the anti-blood clotting drug dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim) as an option ...

[:content [\9 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \T \h \e \space \G \e \r \m \a \n \space \F \e \d \e \r \a \l \space \J \o \i \n \t \space \C \o \m \m \i \t \t \e \e \space \( \G \- \B \A \) \, \space \t \h \e \space \d \e \c \i \s \i \o \n \- \m \a \k \i \n \g \space \b \o \d \y \space \o \f \space \t \h \e \space \s \e \l \f \- \g \o \v \e \r \n \i \n \g \space \h \e \a \l \t \h \c \a \r \e \space \s \y \s \t \e \m \space \i \n \  \G \e \r \m \a \n \y \, \space \r \e \c \e \n \t \l \y \space \c \o \n \f \i \r \m \e \d " ..."]]

The 1 October 2014 issue of the Schedule of Pharmaceutical Benefits is now available.   The schedule contains a number of ...